These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 10100590)
1. Comparative brain tissue distribution of camptothecin and topotecan in the rat. El-Gizawy SA; Hedaya MA Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590 [TBL] [Abstract][Full Text] [Related]
2. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Zamboni WC; Houghton PJ; Hulstein JL; Kirstein M; Walsh J; Cheshire PJ; Hanna SK; Danks MK; Stewart CF Cancer Chemother Pharmacol; 1999; 43(4):269-76. PubMed ID: 10071976 [TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443 [TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Scott DO; Bindra DS; Stella VJ Pharm Res; 1993 Oct; 10(10):1451-7. PubMed ID: 8272406 [TBL] [Abstract][Full Text] [Related]
5. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673 [TBL] [Abstract][Full Text] [Related]
6. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan. Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737 [TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats. Kaneda N; Hosokawa Y; Yokokura T; Awazu S Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983 [TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio. Chen J; Hu RR; Yang XX; Gu W; Tian R; Gong F; Luo L; Fang F; Chen ZP; Cai BC Cancer Chemother Pharmacol; 2013 Oct; 72(4):925-9. PubMed ID: 23934323 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304 [TBL] [Abstract][Full Text] [Related]
11. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253 [TBL] [Abstract][Full Text] [Related]
13. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203 [TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353 [TBL] [Abstract][Full Text] [Related]
16. Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein. Yao S; Petluru P; Parker A; Ding D; Chen X; Huang Q; Kochat H; Hausheer F Cancer Chemother Pharmacol; 2015 Apr; 75(4):719-28. PubMed ID: 25634596 [TBL] [Abstract][Full Text] [Related]
17. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. Bai F; Kirstein MN; Hanna SK; Iacono LC; Johnston B; Stewart CF J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 784(2):225-32. PubMed ID: 12505770 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic potential of camptothecin and topotecan. Clements MK; Jones CB; Cumming M; Daoud SS Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915 [TBL] [Abstract][Full Text] [Related]
19. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988 [TBL] [Abstract][Full Text] [Related]
20. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. Leggas M; Zhuang Y; Welden J; Self Z; Waters CM; Stewart CF J Pharm Sci; 2004 Sep; 93(9):2284-95. PubMed ID: 15295789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]